
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of General Medicine [E. H., I. F., T. Y.], Second Department of Internal Medicine [K. H.], First Department of Surgery [H. Y., Y. M.], Hiroshima University School of Medicine, Hiroshima 734-8551, Japan, and The University of Texas Southwestern Medical Center at Dallas, The Department of Cell Biology and Neuroscience, Dallas, Texas 75235-9039 [J. W. S.]
Amplification of the MYCN gene and high telomerase activity predict a poor prognosis for the patients with neuroblastoma. We used PCR techniques for rapid detection of MYCN gene amplification and human telomerase reverse transcriptase (hTERT) expression in neuroblastoma specimens. The detection of MYCN gene amplification is based on differential PCR in which three primer pairs were used to coamplify a 178-bp fragment of target MYCN gene with two reference gene fragments, a 237-bp of p53 exon 7 and a 120-bp of ß-globin exon 3, in a single tube of 40 surgically resected tumor samples. MYCN amplification was identified by this differential PCR in all 10 samples carrying more than 10 copies (already known to have MYCN gene amplification by Southern blot analysis). There were no false-negative or false-positive cases, and the relative intensity of MYCN bands in the differential PCR correlated significantly with the copy number determined by Southern blot analysis (
= 0.99, P < 0.0001). This protocol was also applicable in the biopsy or aspirated samples, as well as the paraffin-embedded tissues, and in detecting intratumoral heterogeneity. Using RT-PCR procedures, hTERT mRNA expression was detectable in all 13 tumors with high telomerase activity. These nonradioisotopic PCR-based protocols for detecting MYCN gene amplification and hTERT mRNA expression are rapid and reliable and are likely to be useful to determine the biological behavior of neuroblastoma.
This article has been cited by other articles:
![]() |
M. Krams, B. Hero, F. Berthold, R. Parwaresch, D. Harms, and P. Rudolph Full-Length Telomerase Reverse Transcriptase Messenger RNA Is an Independent Prognostic Factor in Neuroblastoma Am. J. Pathol., March 1, 2003; 162(3): 1019 - 1026. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Krams, A. Claviez, K. Heidorn, G. Krupp, R. Parwaresch, D. Harms, and P. Rudolph Regulation of Telomerase Activity by Alternate Splicing of Human Telomerase Reverse Transcriptase mRNA in a Subset of Neuroblastomas Am. J. Pathol., November 1, 2001; 159(5): 1925 - 1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Poremba, C. Scheel, B. Hero, H. Christiansen, K.-L. Schaefer, J.-i. Nakayama, F. Berthold, H. Juergens, W. Boecker, and B. Dockhorn-Dworniczak Telomerase Activity and Telomerase Subunits Gene Expression Patterns in Neuroblastoma: A Molecular and Immunohistochemical Study Establishing Prognostic Tools for Fresh-Frozen and Paraffin-Embedded Tissues J. Clin. Oncol., July 1, 2000; 18(13): 2582 - 2592. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |